Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Juniper Biologics Broadens Caris Life Sciences' Molecular Profiling Distribution in the Middle East and Africa

NextEdge Admin

26 Jun 2024

3 min 6 sec

Juniper Biologics Pte Ltd, based in Singapore and part of The Sylvan Group, has secured exclusive distribution rights for Caris Life Sciences' solid tumour molecular profiling services in both Southeast Asia (SEA) and now the Middle East and Africa (MEA). This partnership aims to extend access to advanced cancer treatment options through Caris' cutting-edge molecular profiling capabilities.

Caris Life Sciences, known for its leadership in precision medicine and AI-driven biotechnology, employs sophisticated molecular profiling techniques that encompass DNA, RNA, and protein analysis. This approach provides oncologists with detailed insights into the molecular characteristics of tumors, enabling highly personalized treatment strategies tailored to individual patients. Caris boasts the world's largest cancer analysis platform, featuring advanced technologies such as Whole Exome and Whole Transcriptome Sequencing across more than 23,000 genes. These capabilities empower healthcare providers to make informed decisions that improve patient outcomes, particularly for rare or aggressive cancers.

Raman Singh, CEO of Juniper Biologics, emphasized the transformative impact of Caris' molecular profiling in bridging the gap between cancer biology and treatment selection. The collaboration aims to enhance healthcare delivery by empowering clinicians across the MEA region to adopt precision medicine approaches. This initiative not only expands treatment options but also strives to uplift patient care standards in underserved areas where access to advanced therapies is limited.

David Spetzler, President of Caris Life Sciences, expressed enthusiasm about the partnership, highlighting Caris' commitment to global healthcare transformation through personalized medicine solutions. The expansion into MEA reflects Caris' mission to enable clinicians worldwide to optimize treatment decisions based on comprehensive molecular insights.

This strategic alliance between Juniper Biologics and Caris Life Sciences marks a significant milestone in advancing personalized medicine and enhancing cancer care across Southeast Asia and the Middle East/Africa regions. By leveraging state-of-the-art technologies and strategic collaborations, both companies aim to redefine healthcare standards and improve patient outcomes on a global scale.